Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CASP6 | P55212 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7878524 | 0.85 | TSHR (0.52) | TDP1TSHRSMN1; SMN2TP53HPGD | |
| SCHEMBL1283268 | 0.82 | SMN1; SMN2 (0.57) | TDP1TSHRSMN1; SMN2TP53HPGD | |
| SCHEMBL29833732 | 0.82 | SMN1; SMN2 (0.57) | TDP1TSHRSMN1; SMN2TP53HPGD | |
| SCHEMBL218885 | 0.82 | TDP1 (0.63) | TDP1TSHRSMN1; SMN2TP53HPGD | |
| SCHEMBL4217608 | 0.80 | TDP1 (0.55) | TDP1TSHRSMN1; SMN2TP53HPGD | |
| SCHEMBL3723529 | 0.80 | TDP1 (0.55) | TDP1TSHRSMN1; SMN2TP53HPGD | |
| SCHEMBL31342321 | 0.80 | TDP1 (0.55) | TDP1TSHRSMN1; SMN2TP53HPGD | |
| SCHEMBL27718719 | 0.80 | HPGD (0.55) | TDP1TSHRSMN1; SMN2TP53HPGD | |
| SCHEMBL306584 | 0.80 | TDP1 (0.67) | TDP1TSHRHPGDCYP3A4HIF1A | |
| SCHEMBL29417506 | 0.80 | TDP1 (0.67) | TDP1TSHRHPGDCYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116026941-A | Separation and detection method for nitrobenzene genotoxic impurities in fluvastatin | 重庆医药工业研究院有限责任公司 | 2023-04-28 | — | — | CN | claimed |
| CN-114621106-A | Preparation method of tyrosine kinase drug intermediate | 重庆医药工业研究院有限责任公司 | 2022-06-14 | — | — | CN | claimed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| CN-112028825-B | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生睿创生物科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-3293177-B1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2024-11-27 | — | — | EP | disclosed |
| CN-118311164-A | Method for simultaneously detecting contents of 4-chloro-2-methylphenol and o-phenol | 湖北泰盛化工有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-116026941-A | Separation and detection method for nitrobenzene genotoxic impurities in fluvastatin | 重庆医药工业研究院有限责任公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-116026941-A | Separation and detection method for nitrobenzene genotoxic impurities in fluvastatin | 重庆医药工业研究院有限责任公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-110023288-B | Crystal form, salt form and preparation method of tyrosine kinase inhibitor | 广东众生睿创生物科技有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-114621106-A | Preparation method of tyrosine kinase drug intermediate | 重庆医药工业研究院有限责任公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114621106-A | Preparation method of tyrosine kinase drug intermediate | 重庆医药工业研究院有限责任公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3521276-A1 | CRYSTAL FORM AND SALT FORM OF AND PREPARATION METHOD FOR TYROSINE KINASE INHIBITOR | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-08-07 | — | — | EP | disclosed |
| CN-110023288-A | Crystal form, salt form and the preparation method of tyrosine kinase inhibitor | 广东众生睿创生物科技有限公司 | 2019-07-16 | — | — | CN | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
| CN-103565653-A | Substituted pyrazolone compound as well as using method and application of pyrazolone compound | SUNSHINE LAKE PHARMA CO LTD | 2014-02-12 | — | — | CN | disclosed |
| CN-103539780-A | Substituted pyrazolone compounds, methods of use, and uses thereof | GUANGDONG HEC PHARMACEUTICAL | 2014-01-29 | — | — | CN | disclosed |
| CN-103420986-A | Substituted quinoline compounds, methods of use, and uses thereof | GUANGDONG HEC PHARMACEUTICAL | 2013-12-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ABL1, LCK, ERBB2 | TDP1 1127/4885TSHR 1980/4885SMN1; SMN2 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.